Journal of Clinical Oncology, Vol 8, 1695-1698, Copyright © 1990 by American Society of Clinical Oncology

ARTICLES

Long-term fertility and Leydig cell function in patients treated for germ cell cancer with cisplatin, vinblastine, and bleomycin versus surveillance

SW Hansen, JG Berthelsen and H von der Maase
Department of Oncology, Finsen Institute, Rigshospitalet, Copenhagen, Denmark.

Fertility and Leydig cell function were investigated in 31 patients previously treated for nonseminomatous testicular cancer. Twenty-two patients with metastatic cancer had received cisplatin-based chemotherapy, and the median follow-up was 64 months (range, 42 to 100 months). Nine patients without metastases were treated with orchiectomy alone, and follow-up in this group was a median of 61 months (range, 40 to 77 months). None of the patients have relapsed and retroperitoneal lymph node dissection was not performed in any patient. Both the concentration of spermatozoa and the volume of the remaining testis are significantly reduced in patients who had previously received chemotherapy when compared with patients treated with orchiectomy alone (P less than .05). There were no significant differences between groups when comparing morphology, motility, and penetration of the spermatozoa. Subclinical Leydig cell dysfunction with normal testosterone and elevated luteinizing hormone (LH) was observed in one patient (11%) treated with orchiectomy alone, while 59% of the patients who had received chemotherapy had elevated LH (P less than .05). We conclude that cisplatin-based chemotherapy leads to a persistent impairment of fertility and Leydig cell function in the majority of patients with testicular cancer.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				J. Eberhard, O. Stahl, M. Cwikiel, E. Cavallin-Stahl, Y. Giwercman, E. C. Salmonson, and A. Giwercman Risk factors for post-treatment hypogonadism in testicular cancer patients. Eur. J. Endocrinol., April 1, 2008; 158(4): 561 - 570. [Abstract] [Full Text] [PDF]

				J. E. Brown, S. P. Ellis, P. Silcocks, A. Blumsohn, S. A. Gutcher, C. Radstone, B. W. Hancock, M. Q. Hatton, and R. E. Coleman Effect of chemotherapy on skeletal health in male survivors from testicular cancer and lymphoma. Clin. Cancer Res., November 1, 2006; 12(21): 6480 - 6486. [Abstract] [Full Text] [PDF]

				J.R. Spermon, L. Ramos, A.M.M. Wetzels, C.G.J. Sweep, D.D.M. Braat, L.A.L.M. Kiemeney, and J.A. Witjes Sperm integrity pre- and post-chemotherapy in men with testicular germ cell cancer Hum. Reprod., July 1, 2006; 21(7): 1781 - 1786. [Abstract] [Full Text] [PDF]

				S. J. Howell and S. M. Shalet Spermatogenesis After Cancer Treatment: Damage and Recovery J Natl Cancer Inst Monographs, March 1, 2005; 2005(34): 12 - 17. [Abstract] [Full Text] [PDF]

				P. Sawhney, C. J. Giammona, M. L. Meistrich, and J. H. Richburg Cisplatin-Induced Long-term Failure of Spermatogenesis in Adult C57/Bl/6J Mice J Androl, January 1, 2005; 26(1): 136 - 145. [Abstract] [Full Text] [PDF]

				J. Eberhard, O. Stahl, Y. Giwercman, M. Cwikiel, E. Cavallin-Stahl, K.B. Lundin, P. Flodgren, and A. Giwercman Impact of therapy and androgen receptor polymorphism on sperm concentration in men treated for testicular germ cell cancer: a longitudinal study Hum. Reprod., June 1, 2004; 19(6): 1418 - 1425. [Abstract] [Full Text] [PDF]

				D. J. Vaughn, G. A. Gignac, and A. T. Meadows Long-Term Medical Care of Testicular Cancer Survivors Ann Intern Med, March 19, 2002; 136(6): 463 - 470. [Abstract] [Full Text] [PDF]

				M. T. Meinardi, J. A. Gietema, W. T. A. van der Graaf, D. J. van Veldhuisen, M. A. Runne, W. J. Sluiter, E. G. E. de Vries, P. B. H. Willemse, N. H. Mulder, M. P. van den Berg, et al. Cardiovascular Morbidity in Long-Term Survivors of Metastatic Testicular Cancer J. Clin. Oncol., April 1, 2000; 18(8): 1725 - 1732. [Abstract] [Full Text] [PDF]

				S.-C. J. Yeung, A. C. Chiu, R. Vassilopoulou-Sellin, and R. F. Gagel The Endocrine Effects of Nonhormonal Antineoplastic Therapy Endocr. Rev., April 1, 1998; 19(2): 144 - 172. [Abstract] [Full Text]

				D. M. Green Fertility and Pregnancy Outcome after Treatment for Cancer in Childhood or Adolescence Oncologist, June 1, 1997; 2(3): 171 - 179. [Abstract] [Full Text] [PDF]

				K. L. Lenz and A. W. Valley Review : Infertility after chemotherapy: A review of the risks and strategies for prevention Journal of Oncology Pharmacy Practice, January 1, 1996; 2(2): 75 - 100. [Abstract] [PDF]

				J. A. Gietema, D. Th. Sleijfer, P. H. B. Willemse, H. S. Koops, E. van Ittersum, W. M. M. Verschuren, D. Kromhout, W. J. Sluiter, N. H. Mulder, and E. G. E. de Vries Long-term Follow-up of Cardiovascular Risk Factors in Patients Given Chemotherapy for Disseminated Nonseminomatous Testicular Cancer Ann Intern Med, May 1, 1992; 116(9): 709 - 715. [Abstract] [PDF]